局限性玻璃体切除术治疗视力损害性飞蚊症的的成本效果分析
术后视功能问卷(VFQ-39)平均提高19%,对比敏感度(CSF)提高53%,最佳矫正视力(BCVA)提高13.5%;增量成本效用比为1574美元/质量调整生命年(QALY),提示该手术具有临床有效性和高度成本效果。
要点
- 局限性玻璃体切除术改善视力损害性飞蚊症患者的BCVA、CSF和生活质量。
- 增量成本效用比为1574美元/QALY,优于白内障手术等对照干预。
- 无玻璃体后脱离(PVD)的近视患者成本效用比最低(1338美元/QALY)。
核心结论
- 局限性玻璃体切除术治疗视力损害性飞蚊症具有临床有效性,可改善BCVA、CSF和患者幸福感。
- 该手术具有高度成本效果,平均成本效用比为1574美元/QALY,优于白内障手术(2262美元/QALY)、弱视治疗(2710美元/QALY)和视网膜脱离修复(45304美元/QALY)。
研究设计与样本
- 回顾性、干预性病例系列及第三方支付方成本效用分析。
- 患者术前和术后完成国家眼科研究所视功能问卷(VFQ-39),并接受BCVA和CSF测量;进行参考案例成本效用分析。
主要发现
- 术后VFQ-39平均提高19%(P < 0.00001),总体一般视力提高27%,非近视PVD组提高37%(各P < 0.00001)。
- VFQ-39与时间权衡效用相关性表明生活质量改善14.4%。
- 术后平均BCVA提高13.5%(P < 0.00001),CSF提高53%(P < 0.00001)。
- 局限性玻璃体切除术带来的增量患者价值增益为2.38 QALYs,2018年美国实际美元平均成本效用比为1574美元/QALY。
- 无PVD的近视患者成本效用比在所有组中最低(1338美元/QALY)。
关键数值与推荐
- 术后VFQ-39平均提高19%(P < 0.00001)。
- 术后BCVA平均提高13.5%(P < 0.00001),CSF提高53%(P < 0.00001)。
- 增量成本效用比为1574美元/QALY(2018年美国实际美元)。
- 无PVD的近视患者成本效用比为1338美元/QALY。
临床怎么用
- 对于视力损害性飞蚊症患者,局限性玻璃体切除术可考虑作为改善视功能和生活质量的治疗选择。
- 该手术具有高度成本效果,尤其对于无PVD的近视患者成本效用比更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients afflicted with clinically significant vitreous floaters suffer from vision-degrading myodesopsia, characterized by impairment in contrast sensitivity function (CSF) and decreased quality of life. This study determined the cost-effectiveness of limited vitrectomy for this condition. DESIGN: Retrospective, interventional case series and third-party insurer cost-utility analysis. METHODS: Sixty-seven patients suffering from unilateral vitreous floaters (20 non-myopic patients with posterior vitreous detachment [PVD]; 17 myopic patients [>-2 diopters] without PVD; 30 myopic patients with PVD) completed the National Eye Institute Visual Function Questionnaire (VFQ-39) and were tested with best-corrected visual acuity (BCVA) and CSF measurements before and after limited vitrectomy. A reference case cost-utility analysis was performed. RESULTS: The mean VFQ-39 increased 19% (P < 0.00001) after surgery, with general vision improving 27% for the entire group and 37% for non-myopic PVD (P < 0.00001 for each). VFQ-39 correlations with time tradeoff utilities indicated a 14.4% improvement in quality of life. Mean BCVA improved 13.5% postoperatively (P < 0.00001) and CSF improved 53% (P < 0.00001). The incremental patient value gain conferred by limited vitrectomy was 2.38 quality-adjusted life-years (QALYs), and the average cost-utility ratio in 2018 U.S. real dollars was $1,574/QALY. CONCLUSIONS: Limited vitrectomy for vision-degrading myodesopsia is clinically effective, in that it improves BCVA, CSF, and patient well-being. It is also highly cost-effective ($1,574/QALY), with an average cost-utility ratio vs. no therapy that is superior to cataract surgery ($2,262/QALY), amblyopia therapy ($2,710/QALY), and retinal detachment repair ($45,304/QALY). Myopic patients without PVD had the lowest cost-utility ratio of all ($1,338/QALY).
引用
- Rostami B, Nguyen-Cuu J, Brown G, et al. Cost-Effectiveness of Limited Vitrectomy for Vision-Degrading Myodesopsia. Am J Ophthalmol. 2019. PMID: 30849342. doi:10.1016/j.ajo.2019.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。